Upside | ||||||
---|---|---|---|---|---|---|
VRTX | 8.32% | aa.aa | 440.66 | +0.46% | 6,691 | |
AMGN | 8.10% | aa.aa | 275.85 | +1.26% | 10,413 | |
GILD | 8.06% | aa.aa | 106.16 | +3.57% | 28,078 | |
REGN | 7.20% | aa.aa | 596.54 | +0.37% | 4,301 | |
AZN | 4.53% | aa.aa | 69.69 | +1.28% | 23,314 | |
ALNY | 4.20% | aa.aa | 291.86 | +2.34% | 5,181 | |
BIIB | 2.07% | aa.aa | 129.44 | +3.07% | 5,853 | |
ARGX | 2.06% | aa.aa | 578.10 | +2.20% | 1,282 | |
SMMT | 1.95% | aa.aa | 24.010 | +0.59% | 29,480 | |
SNY | 1.67% | aa.aa | 52.24 | +1.08% | 11,477 |
Invesco Exchange-Traded Fund Trust II - Invesco Nasdaq Biotechnology ETF is an exchange traded fund launched and managed by Invesco Capital Management LLC. The fund invests in public equity markets. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, biotechnology, pharmaceuticals sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the Nasdaq Biotechnology Index, by using full replication technique. Invesco Exchange-Traded Fund Trust II - Invesco Nasdaq Biotechnology ETF was formed on June 9, 2021 and is domiciled in the United States.